175 related articles for article (PubMed ID: 27775892)
1. Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction.
Gollner A; Rudolph D; Arnhof H; Bauer M; Blake SM; Boehmelt G; Cockroft XL; Dahmann G; Ettmayer P; Gerstberger T; Karolyi-Oezguer J; Kessler D; Kofink C; Ramharter J; Rinnenthal J; Savchenko A; Schnitzer R; Weinstabl H; Weyer-Czernilofsky U; Wunberg T; McConnell DB
J Med Chem; 2016 Nov; 59(22):10147-10162. PubMed ID: 27775892
[TBL] [Abstract][Full Text] [Related]
2. Targeted Synthesis of Complex Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2-p53 Inhibitors.
Gollner A; Weinstabl H; Fuchs JE; Rudolph D; Garavel G; Hofbauer KS; Karolyi-Oezguer J; Gmaschitz G; Hela W; Kerres N; Grondal E; Werni P; Ramharter J; Broeker J; McConnell DB
ChemMedChem; 2019 Jan; 14(1):88-93. PubMed ID: 30458062
[TBL] [Abstract][Full Text] [Related]
3. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
[TBL] [Abstract][Full Text] [Related]
4. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
5. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
Yu S; Qin D; Shangary S; Chen J; Wang G; Ding K; McEachern D; Qiu S; Nikolovska-Coleska Z; Miller R; Kang S; Yang D; Wang S
J Med Chem; 2009 Dec; 52(24):7970-3. PubMed ID: 19928922
[TBL] [Abstract][Full Text] [Related]
6. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
7. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.
Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C
Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774
[TBL] [Abstract][Full Text] [Related]
9. Computational analysis of spiro-oxindole inhibitors of the MDM2-p53 interaction: insights and selection of novel inhibitors.
Huang W; Cai L; Chen C; Xie X; Zhao Q; Zhao X; Zhou HY; Han B; Peng C
J Biomol Struct Dyn; 2016; 34(2):341-51. PubMed ID: 25808617
[TBL] [Abstract][Full Text] [Related]
10. Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3'-Spirooxindoles Fused with Tetrahydrothiopyrans as Novel p53-MDM2 Inhibitors.
Wang S; Jiang Y; Wu S; Dong G; Miao Z; Zhang W; Sheng C
Org Lett; 2016 Mar; 18(5):1028-31. PubMed ID: 26883465
[TBL] [Abstract][Full Text] [Related]
11. Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.
Aguilar A; Sun W; Liu L; Lu J; McEachern D; Bernard D; Deschamps JR; Wang S
J Med Chem; 2014 Dec; 57(24):10486-98. PubMed ID: 25496041
[TBL] [Abstract][Full Text] [Related]
12. Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors.
Wurz RP; Cee VJ
J Med Chem; 2019 Jan; 62(2):445-447. PubMed ID: 30575392
[TBL] [Abstract][Full Text] [Related]
13. FOLICation: engineering approved drugs as potential p53-MDM2 interaction inhibitors for cancer therapy.
Patil SP
Med Hypotheses; 2013 Dec; 81(6):1104-7. PubMed ID: 24210632
[TBL] [Abstract][Full Text] [Related]
14. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.
Zhao Y; Yu S; Sun W; Liu L; Lu J; McEachern D; Shargary S; Bernard D; Li X; Zhao T; Zou P; Sun D; Wang S
J Med Chem; 2013 Jul; 56(13):5553-61. PubMed ID: 23786219
[TBL] [Abstract][Full Text] [Related]
15. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.
Chen H; Luo D; Zhang L; Lin X; Luo Q; Yi H; Wang J; Yan X; Li B; Chen Y; Liu X; Zhang H; Liu S; Qiu M; Yang D; Jiang N
Oncotarget; 2017 Jun; 8(26):43008-43022. PubMed ID: 28498808
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
[TBL] [Abstract][Full Text] [Related]
17. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.
Shangary S; Qin D; McEachern D; Liu M; Miller RS; Qiu S; Nikolovska-Coleska Z; Ding K; Wang G; Chen J; Bernard D; Zhang J; Lu Y; Gu Q; Shah RB; Pienta KJ; Ling X; Kang S; Guo M; Sun Y; Yang D; Wang S
Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3933-8. PubMed ID: 18316739
[TBL] [Abstract][Full Text] [Related]
18. One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors.
Ibrahim HS; Eldehna WM; Fallacara AL; Ahmed ER; Ghabbour HA; Elaasser MM; Botta M; Abou-Seri SM; Abdel-Aziz HA
Future Med Chem; 2018 Dec; 10(24):2771-2789. PubMed ID: 30526032
[TBL] [Abstract][Full Text] [Related]
19. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
Zhang Z; Ding Q; Liu JJ; Zhang J; Jiang N; Chu XJ; Bartkovitz D; Luk KC; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
Bioorg Med Chem; 2014 Aug; 22(15):4001-9. PubMed ID: 24997575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
